Wyniki wyszukiwania

1

Lack of squamous cell lung carcinoma in vitro chemosensitivity to various drug regimens in the adenosine triphosphate cell viability chemosensitivity assay

100%

Vogt U., Striehn E., Bosse U., Klinke F., Falkiewicz B.

Acta Biochimica Polonica

|

1999

|

tom 46

|

nr 2

A pilot study on squamous cell lung carcinoma (LC) chemosensitivity in adenosine triphosphate cell viability chemosensitivity assay (ATP-CVA) was performed. Besides the histological investigation, a modified ATP-CVA was used for the analysis of cancer cell chemosensitivity to four drug regimens, including topotecan, a promising agent for non-small-cell lung cancer (NSCLC) chemotherapy. Results of in vitro chemosensitivity testing showed chemoresistance or only weak response in the predominant amount of tumors.

2

Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay

100%

Vogt U., Falkiewicz B., Bielawski K., Bosse U., Schlotter C. M.

Acta Biochimica Polonica

|

2000

|

tom 47

|

nr 1

A pilot study on relationships of selected molecular factors [erbB-1, erbB-2, erbB-3, and c-myc oncogene average gene copy numbers (AGCN); steroid receptors and pS2 gene expression; tumor cells' DNA values] to the ex vivo chemosensitivity of ovarian cancer in a modified adenosine triphosphate cell viability chemosensitivity assay (ATP-CVA), was performed. Despite the relatively small number of patients, numerous correlations among the factors tested were found. Nevertheless, only c-myc gene dosage positively affected ex vivo chemosensitivity of tumors tested.

3

C-myc oncogene gene dosage, serum CEA and CA-15.3 antigen levels, and cellular DNA values in relation to ex vivo chemosensitivity of primary human breast cancer

80%

Falkiewicz B., Schlotter C. M., Bosse U., Bielawski K., Vogt U.

Acta Biochimica Polonica

|

2000

|

tom 47

|

nr 1

A pilot study on relationships of selected molecular factors (c-myc oncogene average gene copy numbers (AGCN); serum CEA and CA 15.3 antigen levels; tumor cells' DNA values), to the ex vivo chemosensitivity of primary female human breast cancer in a modified adenosine triphosphate cell viability chemosensitivity assay (ATP-CVA), was performed. Four drug combinations were tested. A group of 75 cases of female primary breast cancer was assessed. Numerous correlations were found among molecular factors tested but none, with the exception of tumor grading, of these reflected ex vivo chemosensitivity of tumors tested. The results suggest that the parameters tested may not be important factors related to adjuvant chemoresponsiveness of primary human breast cancer to tested drug combinations

4

Cytokines in the treatment of hematological disorders: recent progress and perspectives

61%

Robak T.

Archivum Immunologiae et Therapiae Experimentalis

|

1996

|

tom 44

|

nr 1

Ograniczanie wyników

3 Acta Biochimica Polonica

1 Archivum Immunologiae et Therapiae Experimentalis

3 Bosse U.

3 Falkiewicz B.

3 Vogt U.

2 Bielawski K.

2 Schlotter C. M.

1 Klinke F.

1 Robak T.

1 Striehn E.

2 2000

1 1999

1 1996

Lack of squamous cell lung carcinoma in vitro chemosensitivity to various drug regimens in the adenosine triphosphate cell viability chemosensitivity assay

Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay

C-myc oncogene gene dosage, serum CEA and CA-15.3 antigen levels, and cellular DNA values in relation to ex vivo chemosensitivity of primary human breast cancer

Cytokines in the treatment of hematological disorders: recent progress and perspectives